Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant

Uloženo v:
Podrobná bibliografie
Vydáno v:Haematologica (Roma) Ročník 108; číslo 2; s. 615 - 620
Hlavní autoři: Chen, George, Herr, Megan, Nowak, Jan, Ho, Christine, Almyroudis, Nikolaos, Attwood, Kristopher, Bonnewell, John, Walsh, Marissa, Segal, Brahm, Ross, Maureen, McCarthy, Philip, Hahn, Theresa
Médium: Journal Article
Jazyk:angličtina
Vydáno: Italy Fondazione Ferrata Storti 01.02.2023
Ferrata Storti Foundation
Témata:
Antigens, CD19
Cytomegalovirus
Humans
Immunotherapy, Adoptive - adverse effects
Letter to the Editor
Lymphoma, B-Cell - therapy
Receptors, Antigen, T-Cell
T-Lymphocytes
ISSN:0390-6078, 1592-8721, 1592-8721
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Bibliografie:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 23
Disclosures
BS receives research funding from NextCure and Apellis and is on the advisory board for NextCure. GLC receives clinical research funding from Actinium, AlloVir, and Takeda. PLM receives consultancy fees / honoraria / research funding from Bluebird Bio, BMS/Celgene/Juno, Fate Therapeutics, Hikma, Janssen, Karyopharm, Magenta Therapeutics, Novartis, Oncopeptides, Partner Therapeutics, Sanofi, Starton Therapeutics, and Takeda. The remaining authors have no conflicts of interest to disclose.
Contributions
GLC wrote the manuscript. GLC and MH designed research. GLC, MH, JN, NA, NW.JB,CH, MR,BS, PLM, and TH provided data. GLC, MH, BS, PLM, and TH analyzed data. All authors read and commented on the manuscript.
Please address requests for data to GC.
Data-sharing statement
ISSN:0390-6078
1592-8721
1592-8721
DOI:10.3324/haematol.2022.281719